LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Bio-Techne Corp

Gesloten

SectorGezondheidszorg

53.01 3.07

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

51.53

Max

53.25

Belangrijke statistieken

By Trading Economics

Inkomsten

-40M

-18M

Verkoop

783K

317M

K/W

Sectorgemiddelde

112.217

35.293

EPS

0.53

Dividendrendement

0.62

Winstmarge

-5.577

Werknemers

3,100

EBITDA

-61M

6.4M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.11% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.62%

3.07%

Volgende Winsten

29 okt 2025

Volgende dividenddatum

21 nov 2025

Volgende Ex Dividend datum

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-861M

8B

Vorige openingsprijs

49.94

Vorige sluitingsprijs

53.01

Nieuwssentiment

By Acuity

27%

73%

69 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Bio-Techne Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 sep 2025, 23:56 UTC

Populaire aandelen

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 sep 2025, 22:01 UTC

Belangrijke Marktbewegers

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 sep 2025, 20:51 UTC

Acquisities, Fusies, Overnames

UPS Terminates Plan to Buy Estafeta

18 sep 2025, 20:31 UTC

Winsten

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 sep 2025, 20:26 UTC

Winsten

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 sep 2025, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 sep 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 sep 2025, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

18 sep 2025, 23:40 UTC

Marktinformatie

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 sep 2025, 23:31 UTC

Marktinformatie

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 sep 2025, 22:03 UTC

Winsten

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 sep 2025, 22:01 UTC

Winsten

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 sep 2025, 21:56 UTC

Winsten

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 sep 2025, 21:54 UTC

Winsten

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 sep 2025, 21:48 UTC

Winsten

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 sep 2025, 21:47 UTC

Winsten

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 sep 2025, 21:17 UTC

Winsten

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 sep 2025, 21:07 UTC

Winsten

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sep 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

18 sep 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

18 sep 2025, 20:22 UTC

Acquisities, Fusies, Overnames

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 sep 2025, 20:22 UTC

Acquisities, Fusies, Overnames

United Parcel Service Terminates Plan to Buy Estafeta

18 sep 2025, 20:20 UTC

Acquisities, Fusies, Overnames

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 sep 2025, 20:18 UTC

Winsten

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 sep 2025, 20:18 UTC

Winsten

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 sep 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

18 sep 2025, 20:07 UTC

Winsten

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sep 2025, 20:03 UTC

Winsten

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Peer Vergelijking

Prijswijziging

Bio-Techne Corp Prognose

Koersdoel

By TipRanks

28.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 66 USD  28.11%

Hoogste 75 USD

Laagste 53 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bio-Techne Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technische score

By Trading Central

49.67 / 50.24Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

69 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat